Valneva SE

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

26 11 2024 11:45:00 提供 Nasdaq GlobeNewswire

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

13 11 2024 11:45:00 提供 Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

12 11 2024 01:00:00 提供 Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

07 11 2024 01:00:00 提供 Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: October 31, 2024

06 11 2024 02:30:00 提供 Nasdaq GlobeNewswire

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

21 10 2024 11:45:00 提供 Nasdaq GlobeNewswire

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

16 10 2024 11:45:00 提供 Nasdaq GlobeNewswire

Valneva Hosts Investor Day in New York City

10 10 2024 01:00:00 提供 Nasdaq GlobeNewswire

Valneva SE - Declaration of shares and voting rights - September 30, 2024

04 10 2024 01:30:00 提供 Nasdaq GlobeNewswire

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

03 10 2024 01:00:00 提供 Nasdaq GlobeNewswire

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

18 9 2024 01:00:00 提供 Nasdaq GlobeNewswire

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

13 9 2024 02:30:00 提供 Nasdaq GlobeNewswire

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros

12 9 2024 16:05:00 提供 Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: August 31, 2024

04 9 2024 12:00:00 提供 Nasdaq GlobeNewswire

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

03 9 2024 01:00:00 提供 Nasdaq GlobeNewswire

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

13 8 2024 01:00:00 提供 Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: July 31, 2024

06 8 2024 02:30:00 提供 Nasdaq GlobeNewswire

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

01 8 2024 01:00:00 提供 Nasdaq GlobeNewswire

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

22 7 2024 01:00:00 提供 Nasdaq GlobeNewswire

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion  

17 7 2024 16:00:00 提供 Nasdaq GlobeNewswire